Notwithstanding encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from managed care entities. The companies are typically creating barriers to reimbursement, like steep cost restrictions and approval processes that hinder patient acc… Read More